EGFR and non-small cell lung carcinoma: In a phase II trial, patients with stage IV EGFR mutated NSCLC were randomized after 8 weeks of erlotinib to continuing erlotinib monotherapy or to erlotinib plus emibetuzumab 750 mg infusion every 2 weeks.